Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing incidence of neuroendocrine tumors
3.2.1.2 Development of new treatments
3.2.1.3 Supportive government policies, grants, and funding for research in oncology
3.2.2 Industry pitfalls & challenges
3.2.2.1 High cost of development
3.2.2.2 Lack of awareness among the people
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Pipeline analysis
3.6 Porter's analysis
3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Therapy, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Somatostatin analogs (SSAs)
5.3 Targeted therapy
5.4 Chemotherapy
5.5 Other therapies
Chapter 6 Market Estimates and Forecast, By Indication, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Lungs NET
6.3 Pancreatic NET
6.4 Gastrointestinal NET
6.5 Other indications
Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Oral
7.3 Parenteral
Chapter 8 Market Estimates and Forecast, By End-Use, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 Hospitals & clinics
8.3 Cancer treatment centers
8.4 Other end-users
Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
9.1 Key trends
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Netherlands
9.3.7 Rest of Europe
9.4 Asia Pacific
9.4.1 China
9.4.2 Japan
9.4.3 India
9.4.4 Australia
9.4.5 South Korea
9.4.6 Rest of Asia Pacific
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Rest of Latin America
9.6 Middle East and Africa
9.6.1 South Africa
9.6.2 Saudi Arabia
9.6.3 UAE
9.6.4 Rest of Middle East and Africa
Chapter 10 Company Profiles
10.1 AVEO Pharmaceuticals, Inc.
10.2 Boehringer Ingelheim International GmbH
10.3 Bristol-Myers Squibb
10.4 Eli Lilly & Company
10.5 F. Hoffmann-La Roche Ltd.
10.6 Hutchison MediPharma Limited
10.7 Ipsen
10.8 Jubilant Life Sciences Ltd.
10.9 Lantheus Holdings, Inc. (Progenics Pharmaceuticals)
10.10 Novartis AG
10.11 Pfizer Inc.
10.12 Tarveda Therapeutics
